GILEAD SCIENCES, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- GILEAD SCIENCES, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $355.00M, a 32.64% decline year-over-year.
- GILEAD SCIENCES, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $419.00M, a 42.60% decline year-over-year.
- GILEAD SCIENCES, INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $230.00M, a 34.29% decline year-over-year.
- GILEAD SCIENCES, INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $435.00M, a 45.00% increase year-over-year.
- GILEAD SCIENCES, INC. payments for repurchase of common stock for fiscal 2025 was $1.92B, a 67.13% increase from fiscal 2024.
- GILEAD SCIENCES, INC. payments for repurchase of common stock for fiscal 2024 was $1.15B, a 15.00% increase from fiscal 2023.
- GILEAD SCIENCES, INC. payments for repurchase of common stock for fiscal 2023 was $1.00B, a 28.37% decline from fiscal 2022.
- GILEAD SCIENCES, INC. payments for repurchase of common stock for fiscal 2022 was $1.40B, a 155.68% increase from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $355.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.44B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $419.00M 10-Q · filed 2026-05-07 | $1.61B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $230.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.92B 10-K · filed 2026-02-24 |
| 2025-09-30 | $435.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.04B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $527.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.91B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $730.00M 10-Q · filed 2026-05-07 | $1.48B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $350.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.15B 10-K · filed 2026-02-24 |
| 2024-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $950.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $100.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $950.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $400.00M 10-Q · filed 2025-05-07 | $1.00B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $150.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.00B 10-K · filed 2026-02-24 |
| 2023-09-30 | $300.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.64B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $150.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.52B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $400.00M 10-Q · filed 2024-05-08 | $1.44B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $792.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.40B 10-K · filed 2025-02-28 |
| 2022-09-30 | $180.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $653.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $72.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $618.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $352.00M 10-Q · filed 2023-05-03 | $589.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $49.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $546.00M 10-K · filed 2024-02-23 |
| 2021-09-30 | $145.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $497.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $553.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $309.00M 10-Q · filed 2022-05-04 | $564.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.58B 10-K · filed 2023-02-22 |
| 2020-09-30 | $201.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.69B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $54.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.71B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $1.33B 10-Q · filed 2021-05-06 | $2.24B derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $105.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $1.75B 10-K · filed 2022-02-23 |
| 2019-09-30 | $222.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $2.61B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $588.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.83B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $834.00M 10-Q · filed 2020-05-06 | $2.69B derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $962.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.90B 10-K · filed 2021-02-25 |
| 2018-09-30 | $449.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $2.04B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $450.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.75B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $1.04B 10-Q · filed 2019-05-08 | $1.43B derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $106.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $954.00M 10-K · filed 2020-02-25 |
| 2017-09-30 | $153.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.85B derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $130.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $2.69B derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $565.00M 10-Q · filed 2018-05-09 | $3.57B derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $1.00B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $11.00B 10-K · filed 2019-02-26 |
| 2016-09-30 | $1.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $13.05B derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $1.00B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $15.10B derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $8.00B 10-Q · filed 2017-05-10 | $15.00B derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $3.05B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $10.00B 10-K · filed 2018-02-27 |
| 2015-09-30 | $3.05B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $8.95B derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $900.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $7.60B derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $3.00B 10-Q · filed 2016-05-06 | $7.90B derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $2.00B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $5.35B 10-K · filed 2017-02-27 |
| 2014-09-30 | $1.70B 10-Q · filed 2014-11-05 | $3.75B derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-30 | $1.20B 10-Q · filed 2014-08-04 | $2.15B derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-31 | $450.00M 10-Q · filed 2015-05-08 | $949.76M derived: sum of 4 quarters · filed 2016-02-24 |
| 2013-12-31 | $399.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $582.00M 10-K · filed 2016-02-24 |
| 2013-09-30 | $100.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $382.26M derived: sum of 4 quarters · filed 2015-02-25 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $487.45M derived: sum of 4 quarters · filed 2015-02-25 |
| 2013-03-31 | $82.24M 10-Q · filed 2014-05-07 | $728.47M derived: sum of 4 quarters · filed 2015-02-25 |
| 2012-12-31 | $200.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $667.00M 10-K · filed 2015-02-25 |
| 2012-09-30 | $205.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $693.30M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $241.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $1.37B derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $20.77M 10-Q · filed 2013-05-08 | $1.86B derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $226.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $2.38B 10-K · filed 2014-02-25 |
| 2011-09-30 | $883.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $2.77B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $724.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $3.44B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $548.70M 10-Q · filed 2012-05-04 | $4.41B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $615.54M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $4.02B 10-K · filed 2013-02-27 |
| 2010-09-30 | $1.55B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $3.65B derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-06-30 | $1.69B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $2.38B derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-03-31 | $162.52M 10-Q · filed 2011-05-09 | $930.95M derived: sum of 4 quarters · filed 2012-02-23 |
| 2009-12-31 | $242.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $998.50M 10-K · filed 2012-02-23 |
| 2009-09-30 | $288.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $1.51B derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-06-30 | $238.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | $1.47B derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-03-31 | $230.06M 10-Q · filed 2010-05-10 | |
| 2008-12-31 | $753.51M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $1.97B 10-K · filed 2011-02-28 |
| 2008-09-30 | $250.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05 | |
| 2007-12-31 | $487.54M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |